ML-Based ABPA Recurrence Prediction and Clinical Utility

Inclusion Criteria: 1. Aged between 18 and 80 years old. 2. Consistent with the diagnostic consensus criteria for ABPA proposed by the ISHAM-ABPA Working Group. 3. Patients in stable phase of ABPA: newly diagnosed treatment-naive patients or those with prior ABPA exacerbation who achieved at least 50% improvement in symptoms assessed by Likert scale or visual analogue scale (VAS) following initial therapy, accompanied by marked radiological improvement (≥50% reduction in pulmonary opacities) or a minimum 20% decline in serum total IgE level. Exclusion Criteria: 1. Concurrent malignant tumors or severe organ dysfunction involving the heart, brain, kidney and other vital organs. 2. Complicated with severe underlying diseases, including active pulmonary tuberculosis, lung cancer, chronic heart failure (NYHA class Ⅳ), chronic kidney disease stage 5 (CKD 5), decompensated liver cirrhosis, etc. 3. Immunocompromised status, such as human immunodeficiency virus (HIV) infection, long-term oral administration of glucocorticoids or immunosuppressive agents. 4. Pregnant or breastfeeding women. 5. Patients with missing core clinical data or incomplete medical records.